Welcome to the international HTA database

Showing [25396 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of detailed anomaly ultrasound screening in the first trimester: a mixed-methods study
2025	NIHR Health Services and Delivery Research programme	Developing palliative and end-of-life care research partnerships in the North East and North Cumbria: a report on the first year of the RIPEN network
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Adaptive deep brain stimulation in Parkinson's disease]
2025	NIHR Health Services and Delivery Research programme	Intersecting factors of disadvantage and discrimination and their effect on daily life during the coronavirus pandemic: the CICADA-ME mixed-methods study
2025	NIHR Health Services and Delivery Research programme	The spiritual needs and care of children and young people with life-threatening or life-shortening conditions, and parents (SPARK): a mixed-method investigation
2025	NIHR Health Technology Assessment programme	Risk assessment tools for predicting transfusion in surgery: a systematic review and meta-analysis
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Lung cancer treatment algorithm]
2025	National Institute for Health and Care Excellence (NICE)	Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025	NIHR Health Technology Assessment programme	Dismantling behavioural weight management interventions: component network meta-analysis of randomised controlled trials and real-world services
2025	NIHR Health Technology Assessment programme	Behavioural weight management interventions for the treatment of obesity: network meta-analysis of trial and real-world individual participant data
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Digital technology promoting health for children and adolescents - an evidence map]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Confirmed trichomonas vaginalis infection: pharmacological treatment]
2025	NIHR Health Technology Assessment programme	Accuracy and clinical effectiveness of fetal growth monitoring strategies for the prediction of small for gestational age at birth: a systematic review and meta-analysis
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions to formal caregivers for increased patient safety]
2025	NIHR Health Services and Delivery Research programme	Understanding and addressing factors affecting carers’ mental health during end-of-life caregiving: synopsis of meta synthesis of literature and stakeholder collaboration
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[A look at connected objects and their integration into remote monitoring]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Newborn screening for Metachromatic leukodystrophy (MLD)]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[International experiences in home hospitalization: challenges and possible solutions]
2025	NIHR Health Technology Assessment programme	Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs)
2025	NIHR Health Services and Delivery Research programme	Proactive integrated consultation-liaison psychiatry for older medical inpatients: The HOME Study RCT of its effectiveness and cost-effectiveness
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostics of ovarian cancer; test accuracy of algorithm-based diagnostics in cases of suspected ovarian cancer]
2025	NIHR Health Services and Delivery Research programme	Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care costs and patient and staff experiences
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of tenapanor (Phozevel)
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Initiating a diagnostic and therapeutic measure in a person with signs and symptoms of pharyngitis/tonsillitis]
2025	NIHR Health Technology Assessment programme	Compression Hosiery to Avoid the Post-Thrombotic Syndrome: a synopsis of the CHAPS RCT
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Psychometric properties for instruments used to measure core outcomes for provoked vestibulodynia]
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of inclisiran (Leqvio)
2025	Health Information and Quality Authority (HIQA)	Paediatric early warning systems in emergency settings: protocol for a systematic review of clinical guidelines
2025	NIHR Health Technology Assessment programme	Optimal provision of opiate substitution therapy and needle and syringe programmes: a multi-method realist evaluation
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions for behavioural change in the aim of promoting health and preventing disability in the elderly]
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of semaglutide (Wegovy)
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Technology Assessment programme	Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Pharmacological treatment of polycystic ovary syndrome - health and quality of life in the short and long term]
2025	NIHR Health Services and Delivery Research programme	After the disruptive innovation: How remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glofitamab (DLBCL, combination with gemcitabine and oxaliplatin) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Services and Delivery Research programme	Health visiting in the UK in light of the COVID-19 pandemic experience (RReHOPE): study synopsis
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Ritlecitinib tosylate (Litfulo)]
2025	NIHR Health Services and Delivery Research programme	Barriers to and outcomes of unspecified kidney donation in the UK: BOUnD, a mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glofitamab (DLBCL, monotherapy, third line or later) – Benefit assessment according to §35a Social Code Book V]
2025	Haute Autorite de sante (HAS)	[Second-line non-invasive skin imaging techniques, including in vivo reflectance confocal microscopy (RCM), for the diagnosis and preoperative mapping of melanoma]
2025	NIHR Health Services and Delivery Research programme	Enhancing referrals to child and adolescent mental health services: the EN-CAMHS mixed-methods study
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Technology Assessment programme	Interventions that challenge established and accepted clinical practice: lessons learnt from a process evaluation of the STOP-APE trial
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Principles and criteria to guide the use of whole-genome sequencing versus targeted gene sequencing for the detection of somatic variants in oncology]
2025	Agency for Care Effectiveness (ACE)	Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years) – Benefit assessment according to §35a Social Code Book V]
2025	NIHR Health Technology Assessment programme	Learnings from the establishment and delivery of the UK Collaborative Paediatric Palliative Care Research Network
2025	Agency for Care Effectiveness (ACE)	Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Garadacimab (hereditary angioedema) – Addendum to Project A25-41]
2025	Swiss Federal Office of Public Health (FOPH)	Magnesium supplements for muscle cramps and for the prevention of recurrent urinary tract stones
2025	NIHR Health Technology Assessment programme	Establishing palliative care research partnerships in Northern Ireland
2025	Agency for Care Effectiveness (ACE)	Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[IQWiG benefit assessments based on systematic reviews: A comparative overview]
2025	Swiss Federal Office of Public Health (FOPH)	Point-of-care diagnostic tests
2025	NIHR Health Services and Delivery Research programme	Clinical and cost-effectiveness of paramedics working in general practice: a mixed-methods realist evaluation
2025	Agency for Care Effectiveness (ACE)	Atogepant and rimegepant for prophylaxis of migraine
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Perinatal pathway: supporting women in a handicap situation related to a physical disability, an intellectual disability or autism]
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Effectiveness and safety of adaptive radiation therapy in patients with lymphoma, head and neck cancer or lung carcinoma]
2025	Swiss Federal Office of Public Health (FOPH)	Use of multigene-expression tests for breast cancer
2025	NIHR Health Services and Delivery Research programme	Optimisation of the deployment of automated external defibrillators in public places in England
2025	Agency for Care Effectiveness (ACE)	Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025	NIHR Health and Social Care Delivery Program	Optimising the delivery and impacts of interventions to improve hospital doctors’ workplace wellbeing in the NHS: The Care Under Pressure 3 realist evaluation study
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of children with peritoneal carcinomatosis]
2025	NIHR Health Technology Assessment programme	Understanding the effectiveness and underlying mechanisms of lifestyle modification interventions in adults with learning disabilities: a mixed-methods systematic review
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Food allergen-specific IgG4 (immunoglobulin G4) measurement by immunoassay]
2025	National Institute for Health and Care Excellence (NICE)	Guselkumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 1094
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Efficacy and safety of non-invasive brain stimulation therapies for the neurorehabilitation of patients with stroke]
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Blood levels testing of imatinib and its active metabolite by high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2025	National Institute for Health and Care Excellence (NICE)	Guselkumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 1095
2025	Basque Office for Health Technology Assessment (OSTEBA)	[Magnetic nanoparticles and a magnetic field generator for inducing hyperthermia in the treatment of pancreatic cancer]
2025	National Institute for Health and Care Excellence (NICE)	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over. NICE technology appraisal guidance 1044
2025	National Institute for Health and Care Excellence (NICE)	Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over. NICE technology appraisal guidance 1093
2025	Basque Office for Health Technology Assessment (OSTEBA)	[CT-guided percutaneous ablation for lung metastasis using radiofrequency or microwaves in patients who are not eligible for curative local and/ or systemic treatment]
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Asynchronous teledermatology as a mechanism for triage and patient referral between primary and specialty care and to support the diagnosis of dermatologic conditions]
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer. NICE technology appraisal guidance 1092
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of genetic tests related to hearing loss and their role in neonatal population screening]
2025	National Institute for Health and Care Excellence (NICE)	Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments. NICE technology appraisal guidance 1091
2025	National Institute for Health and Care Excellence (NICE)	Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma. NICE technology appraisal guidance 1090
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Autonomous diagnostic system (AI) for patients with diabetic retinopathy]
2025	National Institute for Health and Care Excellence (NICE)	Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 1089
2025	Malaysian Health Technology Assessment (MaHTAS)	Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer
2025	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety and efficacy of guided imagery for the control of chronic pain]
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1039
2025	NIHR Health Services and Delivery Research programme	How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis
2025	National Institute for Health and Care Excellence (NICE)	Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. NICE technology appraisal guidance 1088
2025	Malaysian Health Technology Assessment (MaHTAS)	3D-printing for orthosis, prosthesis and exoskeleton
2025	National Institute for Health and Care Excellence (NICE)	Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. NICE technology appraisal guidance 1040
2025	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of delayed antibiotic prescription in the treatment of acute upper respiratory tract infections]
2025	National Institute for Health and Care Excellence (NICE)	Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence. NICE technology appraisal guidance 1086
2025	Malaysian Health Technology Assessment (MaHTAS)	Microwave ablation for kidney and liver tumours
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2025	Health Technology Wales (HTW)	Smartphone based photoplethysmography for the detection and monitoring of atrial fibrillation
2025	National Institute for Health and Care Excellence (NICE)	12 SQ-Bet SLIT for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in people 5 years and over. NICE technology appraisal guidance 1087